Stenting of Bifurcation Lesions
... become a focal area for new research and stent development. The second-generation DES have more biocompatible polymers, and although they have already demonstrated impressive safety results at medium-term follow-up (5–7), additional improvements are anticipated from the newer metallic durable polyme ...
... become a focal area for new research and stent development. The second-generation DES have more biocompatible polymers, and although they have already demonstrated impressive safety results at medium-term follow-up (5–7), additional improvements are anticipated from the newer metallic durable polyme ...
ION - Boston Scientific
... Table 14.5.1 Typical ION Stent System compliance...............................................18 15 WARRANTY.............................................................................................................................18 ...
... Table 14.5.1 Typical ION Stent System compliance...............................................18 15 WARRANTY.............................................................................................................................18 ...
List of abbreviations - Therapeutic Goods Administration
... of metastatic carcinoma of the breast after failure of anthracycline therapy. The application was submitted by Specialised Therapeutics Australia Pty Ltd, on behalf of Abraxis BioScience Australia Pty Ltd (an indirect subsidiary of Celgene Corporation).The proposed extension of indication is: Abraxa ...
... of metastatic carcinoma of the breast after failure of anthracycline therapy. The application was submitted by Specialised Therapeutics Australia Pty Ltd, on behalf of Abraxis BioScience Australia Pty Ltd (an indirect subsidiary of Celgene Corporation).The proposed extension of indication is: Abraxa ...
Pathways of spindle assembly
... plate [6,43]. Although both Kid and chromokinesin localize to chromosomes, however, their function has not yet been determined. Nod appears to be necessary for achiasmatic chromosome alignment to the metaphase plate during meiosis, suggesting that it interacts with spindle microtubules to produce po ...
... plate [6,43]. Although both Kid and chromokinesin localize to chromosomes, however, their function has not yet been determined. Nod appears to be necessary for achiasmatic chromosome alignment to the metaphase plate during meiosis, suggesting that it interacts with spindle microtubules to produce po ...
Antagonistic microtubule-sliding motors position
... carrying a null allele for Ncd (termed cand; ref. 27) with the antiKLP61F antibodies (Fig. 3). In striking contrast to results obtained in wild-type embryos, the inhibition of KLP61F in an Ncd-null background did not inhibit the formation of bipolar metaphase spindles (Fig. 3a). Although the spindle ...
... carrying a null allele for Ncd (termed cand; ref. 27) with the antiKLP61F antibodies (Fig. 3). In striking contrast to results obtained in wild-type embryos, the inhibition of KLP61F in an Ncd-null background did not inhibit the formation of bipolar metaphase spindles (Fig. 3a). Although the spindle ...
Docetaxel in non-small cell lung cancer
... (Taxol®) is derived from the bark of the North American yew tree. Taxanes selectively bind to the β-subunit of polymerized tubulin at sites distinct from those of the vinca alkaloids and colchicines [7–10]. Vinca alkaloids work to destabilize microtubule networks while, in contrast, the taxanes prom ...
... (Taxol®) is derived from the bark of the North American yew tree. Taxanes selectively bind to the β-subunit of polymerized tubulin at sites distinct from those of the vinca alkaloids and colchicines [7–10]. Vinca alkaloids work to destabilize microtubule networks while, in contrast, the taxanes prom ...
TAXUS® Express2 - Boston Scientific
... minimize release into the blood stream. Both the amount of drug and release rate have been determined so that healing can occur while allowing the processes leading to restenosis to be minimized, thus reducing the need for additional treatment in the stented area. The TAXUS Express Stent uses a very ...
... minimize release into the blood stream. Both the amount of drug and release rate have been determined so that healing can occur while allowing the processes leading to restenosis to be minimized, thus reducing the need for additional treatment in the stented area. The TAXUS Express Stent uses a very ...
TAXUS™ Liberte™ Paclitaxel-Eluting Coronary Stent System
... Preparation for the Procedure Your doctor will instruct you on how to prepare for the angioplasty procedure and stent implantation procedure prior to being admitted to the hospital. Your doctor may ask you to take aspirin and other prescribed medications for several days before the procedure. This i ...
... Preparation for the Procedure Your doctor will instruct you on how to prepare for the angioplasty procedure and stent implantation procedure prior to being admitted to the hospital. Your doctor may ask you to take aspirin and other prescribed medications for several days before the procedure. This i ...
Feasibility, Safety, and Efficacy of a Novel Polymeric Pimecrolimus
... I. Patrick Kay, MBCHB,* Peter N. Ruygrok, MD,*†‡ Robert Hatrick, MBBS‡ Auckland, New Zealand; and Minneapolis, Minnesota Objectives The aim of this study was to determine the safety and efficacy of a novel pimecrolimuseluting stent in a porcine coronary model and in a phase I clinical trial. Backgrou ...
... I. Patrick Kay, MBCHB,* Peter N. Ruygrok, MD,*†‡ Robert Hatrick, MBBS‡ Auckland, New Zealand; and Minneapolis, Minnesota Objectives The aim of this study was to determine the safety and efficacy of a novel pimecrolimuseluting stent in a porcine coronary model and in a phase I clinical trial. Backgrou ...
Drug-coated balloon treatment for lower extremity vascular disease
... wall levels of paclitaxel were driven by the sustained retention of drug on the surface of the vessel wall, thereby maintaining a positive concentration gradient from the vessel surface into the arterial wall. Interestingly, at 7 days tissue concentrations began to equalize the vessel surface levels ...
... wall levels of paclitaxel were driven by the sustained retention of drug on the surface of the vessel wall, thereby maintaining a positive concentration gradient from the vessel surface into the arterial wall. Interestingly, at 7 days tissue concentrations began to equalize the vessel surface levels ...
$doc.title
... This presenta6on contains forward-‐looking statements within the meaning of the Private Securi6es Li6ga6on Reform Act with respect to the outlook for expecta6ons for future financial or business performance, strate ...
... This presenta6on contains forward-‐looking statements within the meaning of the Private Securi6es Li6ga6on Reform Act with respect to the outlook for expecta6ons for future financial or business performance, strate ...
doxorubicin and paclitaxel cause different changes in plasma
... the genus Taxus (yews). It is known as a first taxane to demonstrate activity in breast cancer [47,62,65]. Additionally paclitaxel has been shown to have antitumoral activity against ovarian carcinoma, head and non-small cell lung cancers [26,54,59]. Lately it has been also described as an efficacio ...
... the genus Taxus (yews). It is known as a first taxane to demonstrate activity in breast cancer [47,62,65]. Additionally paclitaxel has been shown to have antitumoral activity against ovarian carcinoma, head and non-small cell lung cancers [26,54,59]. Lately it has been also described as an efficacio ...
Sequence-dependent synergism and antagonism between
... DNA and leads to termination of DNA chain elongation. It also inhibits DNA synthesis through inhibition of DNA polymerases leading to cell cycle arrest in the G1/S phase of the cell cycle, which causes apoptosis. GEM toxicity can be increased on inhibition of the ribonucleotide reductase, which bloc ...
... DNA and leads to termination of DNA chain elongation. It also inhibits DNA synthesis through inhibition of DNA polymerases leading to cell cycle arrest in the G1/S phase of the cell cycle, which causes apoptosis. GEM toxicity can be increased on inhibition of the ribonucleotide reductase, which bloc ...
Initiation Slides - Clinical Trials Unit Glasgow
... No significant cardiovascular diseases, including uncontrolled hypertension, clinically relevant cardiac arrhythmia, unstable angina or myocardial infarction within 6 months prior to registration, congestive heart failure ≥NYHA III, severe peripheral vascular disease, clinically significant pericard ...
... No significant cardiovascular diseases, including uncontrolled hypertension, clinically relevant cardiac arrhythmia, unstable angina or myocardial infarction within 6 months prior to registration, congestive heart failure ≥NYHA III, severe peripheral vascular disease, clinically significant pericard ...
Neoadjuvant Therapy for Ovarian Cancer using Bioglycogen(tm)
... In order to slow the progression of tumor cells and to increase sensitivity to chemotherapy agents it will be necessary to focus on the down-regulation of Sod2 in ovarian cancer. The down-regulation of Sod2 will occur by transfection of small interfering RNA, siRNA, into ovarian cancer cells. siRNA ...
... In order to slow the progression of tumor cells and to increase sensitivity to chemotherapy agents it will be necessary to focus on the down-regulation of Sod2 in ovarian cancer. The down-regulation of Sod2 will occur by transfection of small interfering RNA, siRNA, into ovarian cancer cells. siRNA ...
Gemzar - Eli Lilly and Company
... Add 5 mL to the 200-mg vial or 25 mL to the 1-g vial. These dilutions each yield a Gemzar concentration of 38 mg/mL. Complete withdrawal of the vial contents will provide 200 mg or 1 g of Gemzar. Prior to administration the appropriate amount of drug must be diluted with 0.9% Sodium Chloride Injecti ...
... Add 5 mL to the 200-mg vial or 25 mL to the 1-g vial. These dilutions each yield a Gemzar concentration of 38 mg/mL. Complete withdrawal of the vial contents will provide 200 mg or 1 g of Gemzar. Prior to administration the appropriate amount of drug must be diluted with 0.9% Sodium Chloride Injecti ...
Conventional Cancer Treatment
... the phosphorus-nitrogen (P-N) bond, releasing the nitrogen mustard within the cancer cell [4]; this premise was later proven inaccurate [5]. The first clinical trials with cyclophosphamide occurred in 1958, when this drug was found to be the most effective anticancer compound against 33 cancer types ...
... the phosphorus-nitrogen (P-N) bond, releasing the nitrogen mustard within the cancer cell [4]; this premise was later proven inaccurate [5]. The first clinical trials with cyclophosphamide occurred in 1958, when this drug was found to be the most effective anticancer compound against 33 cancer types ...
CDR/04/05 South Essex Cancer Network Final Report
... service administers chemotherapy to local haematology patients only to a BCSH level 1 service. Patients with acute leukaemia requiring intensive chemotherapy are referred to Barts and the London NHS Trust. The Haematology chemotherapy area does not have allocated beds for inpatient treatments howeve ...
... service administers chemotherapy to local haematology patients only to a BCSH level 1 service. Patients with acute leukaemia requiring intensive chemotherapy are referred to Barts and the London NHS Trust. The Haematology chemotherapy area does not have allocated beds for inpatient treatments howeve ...
Breast Cancer
... Diffuse Large B-Cell Lymphoma Title: A Phase III Multicenter, Open-Label Study of Rituximab Faster Infusion Time in Patients with Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphomas. (U4391g) Purpose: To determine how well patients tolerate the second and subsequent infu ...
... Diffuse Large B-Cell Lymphoma Title: A Phase III Multicenter, Open-Label Study of Rituximab Faster Infusion Time in Patients with Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphomas. (U4391g) Purpose: To determine how well patients tolerate the second and subsequent infu ...
Ovarian cancer - Dana-Farber Cancer Institute
... Scientific Vision and Goals for 2015 1. Develop practice-changing clinical trials and trial concepts for gynecologic cancers PARP-inhibitor studies Focus on introducing immunotherapy studies into trial portfolio Biologic combination studies driven by pre-clinical data Novel Phase 1 agents ( ...
... Scientific Vision and Goals for 2015 1. Develop practice-changing clinical trials and trial concepts for gynecologic cancers PARP-inhibitor studies Focus on introducing immunotherapy studies into trial portfolio Biologic combination studies driven by pre-clinical data Novel Phase 1 agents ( ...
Club des Chirurgiens Cardiaques 20
... - Systematic use of one DES brand - Comparison with historical* controls ► Revascularisation GRADIENT ...
... - Systematic use of one DES brand - Comparison with historical* controls ► Revascularisation GRADIENT ...
Drug-Coated Balloons for Coronary Artery Disease
... of stent thrombosis. PEPCAD V was a small dual-center study enrolling patients with bifurcation lesions.28 Both the main and side branches were ballooned with a paclitaxel DCB. The primary endpoint was procedural success, which was defined as residual in-segment stenosis < 30% in the main branch and ...
... of stent thrombosis. PEPCAD V was a small dual-center study enrolling patients with bifurcation lesions.28 Both the main and side branches were ballooned with a paclitaxel DCB. The primary endpoint was procedural success, which was defined as residual in-segment stenosis < 30% in the main branch and ...
New Approval Mechanism for Breast Cancer using pathologic
... indicated for: Neoadjuvant treatment of breast cancer, in combination with trastuzumab and docetaxel for patients with HER2‐positive, locally advanced, inflammatory, or early stage breast cancer (>2 cm in diameter) as part of a complete early breast cancer regimen containing either fluorourac ...
... indicated for: Neoadjuvant treatment of breast cancer, in combination with trastuzumab and docetaxel for patients with HER2‐positive, locally advanced, inflammatory, or early stage breast cancer (>2 cm in diameter) as part of a complete early breast cancer regimen containing either fluorourac ...
Herceptin: monoclonal antibody therapy for metastatic breast cancer
... receive chemotherapy (CRx) alone (either paclitaxel (T) or doxorubicin plus cyclophosphamide (AC)) or chemotherapy in combination with Herceptin® (CRx+H).14 Women who received combination chemotherapy and Herceptin® displayed significantly slower tumor progression, greater tumor reduction by 50% or ...
... receive chemotherapy (CRx) alone (either paclitaxel (T) or doxorubicin plus cyclophosphamide (AC)) or chemotherapy in combination with Herceptin® (CRx+H).14 Women who received combination chemotherapy and Herceptin® displayed significantly slower tumor progression, greater tumor reduction by 50% or ...
Paclitaxel
Paclitaxel is a medication used to treat a number of types of cancer including: ovarian cancer, breast cancer, lung cancer and pancreatic cancer among others. It and docetaxel represent the taxane family of drugs. Paclitaxel's mechanism of action involves interference with the normal breakdown of microtubules during cell division.Common side effects include: hair loss, muscle and joint pains, and diarrhea, among others. It results in a greater risk of infections which can be potentially serious. Use during pregnancy often results in problems in the infant.Paclitaxel was discovered beginning in 1962 as a result of a U.S. National Cancer Institute-funded screening program; being isolated from the bark of the Pacific yew, Taxus brevifolia, thus its name ""taxol"". Developed commercially by Bristol-Myers Squibb, the generic name has changed to ""paclitaxel"" with a trademark becoming Taxol. Other trademarks include Abraxane. Clinicians sometimes use the abbreviation ""PTX"" for paclitaxel, which is discouraged, because it is not a unique identifier.Paclitaxel is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system. There was initially concern over the environmental impact of its initial sourcing from the slow growing Pacific yew. In addition, both the assignment of rights to Bristol-Myers Squibb and the product name were subject to public debate and Congressional hearings.